8-K current report · filed Nov 5, 2026

Bruker Corp (BRKR) 8-K Current Report: November 5, 2026

Item 8.01Item EX-99.1BRKR overview

Short answer

Bruker Corp (BRKR) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Effective July 1, 2026, Bruker reorganized reportable segments from four legacy structures into four new operating segments.

Bruker Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Effective July 1, 2026, Bruker reorganized reportable segments from four legacy structures into four new operating segments
  • BSI BIOS expanded to include BioSpin, SciY, CST, Daltonics, Optics and Mimetas
  • BMID created for Microbiology, Molecular Diagnostics and Biomedical Systems, formerly within BSI CALID
  • Reorganization does not change historical consolidated results, financial position or cash flows
  • Exhibit 99.1 provides recast segment information for investor comparison across 2024-2026 periods

Item EX-99.1 · Exhibit EX-99.1

  • Segment recast separates BioSpin into BIOS and BMID, improving comparability of operating performance
  • Six-month 2026 revenue $1,661.9M, up from $1,598.8M in 2025
  • Six-month 2026 operating loss $55.1M versus $43.7M income, driven by BSI NANO loss $42.7M and Corporate costs $67.8M
  • Recast BIOS generated $757.6M revenue and $58.8M operating income in six months
  • 2025 full-year recast BIOS contributed $1,580.1M revenue and $168.8M operating income, while BMID contributed $508.9M and $88.8M respectively

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Bruker Corp 8-K filings

Get the next BRKR 8-K as it lands

Follow BRKR for push alerts, or ask the research agent what this filing means.